Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo
Lesley‐Ann Martin(Institute of Cancer Research), Mitch Dowsett(Institute of Cancer Research)
Cited by 33
Related Papers
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Mechanisms of tamoxifen resistance
|Endocrine Related Cancer|2004|652
Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial
|Journal of Clinical Oncology|2008|464
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
|JAMA Oncology|2019|425